ConductScience.org, home
Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)
API referenceFor AI assistants

Trial · NCT03852433

Adverse events272

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 272

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
otherAnaemiaBlood and lymphatic system disordersPegylated Interferon Alfa-2a (PEG-IFN Alfa)124
otherAnaemiaBlood and lymphatic system disordersBulevirtide 2 mg/Day + PEG-IFN Alfa450
otherAnaemiaBlood and lymphatic system disordersBulevirtide 10 mg/Day + PEG-IFN Alfa650
otherAnaemiaBlood and lymphatic system disordersBulevirtide 10 mg/Day150
otherLeukopeniaBlood and lymphatic system disordersPegylated Interferon Alfa-2a (PEG-IFN Alfa)1324
otherLeukopeniaBlood and lymphatic system disordersBulevirtide 2 mg/Day + PEG-IFN Alfa2650
otherLeukopeniaBlood and lymphatic system disordersBulevirtide 10 mg/Day + PEG-IFN Alfa2750
otherLeukopeniaBlood and lymphatic system disordersBulevirtide 10 mg/Day850
otherLymphopeniaBlood and lymphatic system disordersPegylated Interferon Alfa-2a (PEG-IFN Alfa)724
otherLymphopeniaBlood and lymphatic system disordersBulevirtide 2 mg/Day + PEG-IFN Alfa1250
otherLymphopeniaBlood and lymphatic system disordersBulevirtide 10 mg/Day + PEG-IFN Alfa1550
otherLymphopeniaBlood and lymphatic system disordersBulevirtide 10 mg/Day550
otherNeutropeniaBlood and lymphatic system disordersPegylated Interferon Alfa-2a (PEG-IFN Alfa)1224
otherNeutropeniaBlood and lymphatic system disordersBulevirtide 2 mg/Day + PEG-IFN Alfa2350
otherNeutropeniaBlood and lymphatic system disordersBulevirtide 10 mg/Day + PEG-IFN Alfa2850
otherNeutropeniaBlood and lymphatic system disordersBulevirtide 10 mg/Day650
otherThrombocytopeniaBlood and lymphatic system disordersPegylated Interferon Alfa-2a (PEG-IFN Alfa)1424
otherThrombocytopeniaBlood and lymphatic system disordersBulevirtide 2 mg/Day + PEG-IFN Alfa2350
otherThrombocytopeniaBlood and lymphatic system disordersBulevirtide 10 mg/Day + PEG-IFN Alfa2450
otherThrombocytopeniaBlood and lymphatic system disordersBulevirtide 10 mg/Day850

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03852433/events

API referenceFor AI assistants